News Column

Trevena, Inc. [TRVN] to Ring The NASDAQ Stock Market Opening Bell

February 18, 2014



ADVISORY, Feb. 18, 2014 (GLOBE NEWSWIRE) --

What:

Trevena, Inc. [TRVN], a clinical stage pharmaceutical company involved in the discovery and development of G protein coupled receptor (GPCR) biased ligands, will visit the NASDAQ MarketSite in Times Square in celebration of its January 31 initial public offering (IPO) on The NASDAQ Stock Market.

In honor of the occasion, Maxine Gowen, President and CEO, will ring the Opening Bell.

Where:

NASDAQ MarketSite – 4 Times Square – 43rd & BroadwayBroadcast Studio

When:

Wednesday, February 19, 2014 – 9:15 a.m. to 9:30 a.m. ET  

Contact:

Eliza Schleifstein

(917) 763-8106

eliza@argotpartners.com  

NASDAQ MarketSite:

Christine Barna 

(646) 441-5310 

Christine.Barna@nasdaqomx.com  

Feed Information: 

Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West

18 mhz Lower

DL 3811 Vertical

FEC 3/4

SR 13.235

DR 18.295411

MOD 4:2:0

DVBS QPSK   

Social Media:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page at:  http://www.facebook.com/NASDAQ

For photos from ceremonies and events visit our Instagram Page: http://instagram.com/nasdaq

For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx

For exciting viral content and ceremony photos visit our Tumblr Page: http://nasdaq.tumblr.com/

Webcast:

A LiveStream of the NASDAQ Opening Bell will be available at: https://new.livestream.com/nasdaq/live  

Or  

http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos:

To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.  

About Trevena, Inc. [TRVN]:

Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena has identified and advanced three differentiated product candidates into the clinic – TRV027 to treat acute heart failure, TRV130 to treat moderate to severe acute pain intravenously, and TRV734 to treat moderate to severe acute and chronic pain orally. Trevena also plans to advance additional product candidates, including a preclinical program focused on central nervous system indications.

About NASDAQ OMX Group:

NASDAQ OMX (Nasdaq:NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, NASDAQ OMX enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. NASDAQ OMX is home to more than 3,200 listed companies with a market value of over $8 trillion. To learn more, visit www.nasdaqomx.com.  

-NDAQA-

company logo

Source: The NASDAQ OMX Group, Inc.


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: GlobeNewswire


Story Tools